RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Johnson & Johnson announced the opening its life science incubator, JLABS @ Shanghai, the world’s largest JLABS and the first in Asia Pacific. The facility has room for over 50 pharmaceutical, medical device, consumer and health tech companies. It has already signed up with 31 resident companies, including the three awardees of the Lung Cancer Innovation QuickFire Challenge. The 4,400-square-meter facility, located in Shanghai’s Zhangjiang Hi-Tech Park, is a collaboration with Shanghai Pharma Engine. JLABS was developed by J&J Innovation, a Division of Johnson & Johnson (China) Investment.
Source: China Biotoday
